Arm Holdings plc - American Depositary Shares (ARM)
282.57
-4.11 (-1.43%)
NASDAQ· Last Trade: Aug 8th, 2:54 PM EDT
Detailed Quote
| Previous Close | 286.68 |
|---|---|
| Open | 298.96 |
| Bid | 282.31 |
| Ask | 283.42 |
| Day's Range | 275.00 - 299.29 |
| 52 Week Range | 100.02 - 452.70 |
| Volume | 3,831,201 |
| Market Cap | - |
| PE Ratio (TTM) | 376.76 |
| EPS (TTM) | 0.8 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 6,169,204 |
Chart
About Arm Holdings plc - American Depositary Shares (ARM)
Arm Holdings plc is a leading technology company that specializes in semiconductor and software design, primarily focusing on microprocessor and system-on-chip (SoC) architectures. Its innovative designs are integral to a wide range of applications, from mobile devices to embedded systems and Internet of Things (IoT) products. Arm's technology enables low power consumption and efficient performance, making it a popular choice among manufacturers and developers in the electronics industry. The company collaborates closely with partners to drive the advancement of next-generation computing and connectivity solutions, playing a crucial role in shaping the future of digital devices and applications. Read More
News & Press Releases
Druckenmiller only owns one "Magnificent Seven" stock.
Via The Motley Fool · August 8, 2026
Big celebrations demand a massive upgrade in your social life. If you have a huge birthday coming up or a corporate celebration, showing up alone is a terr
Via Talk Markets · August 8, 2026

A five-star hotel by itself doesn't make a trip memorable anymore, not for people who've already stayed there. What tends to stick is something smaller and
Via Talk Markets · August 8, 2026
Organic sales grew 5.8% on volume gains and market share expansion across core brands.
Via The Motley Fool · August 7, 2026
Record financing originations and cost cuts drive adjusted EPS growth.
Via The Motley Fool · August 7, 2026
Record data center royalties and AI chip demand double as Arm accelerates server adoption.
Via The Motley Fool · August 7, 2026
Amazon's net margin expanded to 10.8% while Celsius surged 85.5% in revenue, but profitability tells a different story.
Via The Motley Fool · August 7, 2026
Twenty-four immigration providers operating in Tbilisi were assessed for the 2026 Best Immigration Lawyers in Tbilisi ranking published by TbilisiExperts.ge, measured on published fee transparency, verifiable company identity, whether the provider represents clients in administrative appeals, and whether an enquiry written in English reaches a person rather than a form.
Via AB Newswire · August 7, 2026
BIRMINGHAM, Ala. - Cory Watson Attorneys is proud to welcome Chrissy Tubbs as the newest associate attorney to the firm's growing legal team. Tubbs joins the firm with a passion for advocating on behalf of individuals and families whose lives have been impacted by serious injuries and catastrophic events, bringing both compassion and determination to every client she serves.
Via AB Newswire · August 7, 2026
The HEAL and RISE initiative expands into a tri-country movement supporting youth and women's mental health through expanded awareness, advocacy, and community programs across three nations, by Beyond The Call 24/7.
Via Press Release Distribution Service · August 7, 2026
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa
Via MarketBeat · August 7, 2026
Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Chief Executive O
Via MarketBeat · August 7, 2026
Church & Dwight delivered a positive second quarter, with management highlighting broad-based organic sales growth across its divisions and strong consumer d...
Via StockStory · August 7, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via StockStory · August 7, 2026
Today, Aug. 6, 2026, software and cloud names tumbled as investors question valuations while geopolitical tensions added fresh headwinds.
Via The Motley Fool · August 6, 2026
Best PRP P-Shot Clinic in Dubai | Glamorous Clinic in DubaiMen’s wellness is an important part of confidence, comfort, and overall quality of life. With ad
Via Talk Markets · August 6, 2026
ALPHARETTA, GA - August 05, 2026 - Complete Family Healthcare provides whiplash treatment as part of its chiropractic services for patients recovering from motor vehicle accidents and other incidents that...
Via Press Advantage · August 5, 2026
Generate Biomedicines focuses on AI-enabled drug discovery.
Via The Motley Fool · August 5, 2026
Palantir, Microsoft, and ServiceNow look like potential big AI SaaS winners.
Via The Motley Fool · August 5, 2026
The company's 2018 decision to stop reporting unit sales in 2019 means investors aren't seeing the full bullish story. Fortunately, IDC is still keeping score.
Via The Motley Fool · August 5, 2026
China, August 5, 2026 -- MAD COMPONENTS to Return for Third Straight Year at Commercial UAV Expo 2026
Via Press Release Distribution Service · August 5, 2026
They're competitors, but they're decreasingly alike. This is going to make a difference sooner or later.
Via The Motley Fool · August 4, 2026
Arm Holdings (ARM) stock surged over 11% on Tuesday after analysts highlighted 100%+ year-over-year data center royalty growth and strong AI chip demand.
Via Benzinga · August 4, 2026
Modern enterprise security teams face endless streams of network alerts every day. Organizations deploy a unified security platform to consolidate critical
Via Talk Markets · August 4, 2026
For years, biotech investors have often evaluated oncology companies through familiar milestones, including tumor response rates, progression-free survival, and regulatory designations. While each remains important, another endpoint has begun attracting greater attention from researchers and clinicians alike: overall survival .
Via AB Newswire · August 4, 2026